Use mRNA to design new drug against Zika virus.

Zika virus caused Zika virus disease is transmitted by Aedes mosquitoes. The syptoms of zika virus disease are mild fever, skin rash, muscle and joint pain and others. This virus first identified in Uganda and in 1952 is identified in humans in Tanzania. However, study of Zika virus has gained new importance because of the recent spread of the virus in many countries around the globe and its connection to birth defects and a rare neurological disease.

The tertiary structural information can help to development of new drugs for this virus The cryoEM structure map with 3.7 Angestrom resolution (PDBid=5ire) reconstructed and this map showed well-resolved densities corresponding to the α-helices and β-strands. This virus have 180 copies of each of E and M proteins on its surface, there are some transmembrane region in this protein for their anchoring in the lipid membrane.  The role of the E protein is in fusion receptor binding and composed of three ectodomain (D1, D2, and D3). Antibodies design against of this virus target epitops in this ectodomains. The M protein is hidden in hidden under the E protein. In this study, Justin M. Richner and et al developed a vaccine platfom in which lipid nanoprticle encapsulate modified mRNA encoding wild-type or variant ZIKV structural genes.

Sunday 19 February 2017